Abstract
Purpose
The transcription factor Fos-related antigen-1 (Fra-1) has been described to affect the morphology, motility and invasive potential of breast cancer cells. Since tumor cell adhesion plays an essential role in the metastatic process, especially for extravasation from blood vessels, we investigated the influence of Fra-1 on breast cancer cell interactions with the endothelium.
Methods
Using Fra-1-overexpressing MCF7 [weakly invasive, estrogen receptor (ER)-positive] and MDA MB231 (strongly invasive, ER-negative) cells, we performed dynamic cell flow adhesion assays on surfaces coated with E-selectin or with human pulmonary microvascular endothelial cells.
Results
We found a significant increased adhesion of Fra-1-overexpressing MCF7 cells to E-selectin but also to activate endothelial cells, whereas the MDA MB231 cell line showed moderate enhanced cell rolling and tethering on both coated surfaces. These different adhesion behaviors corresponded to an up-regulation of various adhesion-related proteins such as CD44 and integrin α5 in Fra-1-overexpressing MCF7 cells measured by microarray analysis and flow cytometry in comparison with no deregulation of key adhesion molecules observed in Fra-1-overexpressing MDA MB231 cells. In line with these results and based on cDNA microarray data of breast cancer patients (n = 197), high Fra-1 expression significantly correlates with shorter overall survival and higher rate of lung metastasis in ER-positive breast cancer patients (n = 130), but has no impact on the prognosis of patients with ER-negative tumors.
Conclusion
Thus, in addition to its pro-invasive and pro-migratory effect, Fra-1 might influence the metastatic potential of breast cancer cells by changing the expression of adhesion molecules, resulting in increased adherence to endothelial cells under flow conditions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 10:51. doi:10.1186/1741-7015-10-51
Angel P, Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129–157
Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K (1999) Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer 84:533–538. doi:10.1002/(SICI)1097-0215(19991022)84:5<533:AID-IJC16>3.0.CO;2-J
Bamberger AM, Milde-Langosch K, Rossing E, Goemann C, Loning T (2001) Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J Cancer Res Clin Oncol 127:545–550
Barthel SR, Gavino JD, Descheny L, Dimitroff CJ (2007) Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 11:1473–1491. doi:10.1517/14728222.11.11.1473
Belguise K, Kersual N, Galtier F, Chalbos D (2005) FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 24:1434–1444. doi:10.1038/sj.onc.1208312
Blumenthal RD, Hansen HJ, Goldenberg DM (2005) Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res 65:8809–8817. doi:10.1158/0008-5472.CAN-05-0420
Casalino L, De Cesare D, Verde P (2003) Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol 23:4401–4415
Chiappetta G et al (2000) FRA-1 expression in hyperplastic and neoplastic thyroid diseases. Clin Cancer Res 6:4300–4306
Chiappetta G et al (2007) FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer 7:17. doi:10.1186/1471-2407-7-17
Debinski W, Gibo DM (2005) Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 3:237–249. doi:10.1158/1541-7786.MCR-05-0004
Dippel V et al (2013) Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells. J Cancer Res Clin Oncol 139:107–121. doi:10.1007/s00432-012-1306-z
Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ (2004) CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64:5702–5711. doi:10.1158/0008-5472.CAN-04-0389
Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117:5965–5973. doi:10.1242/jcs.01589
Ihnen M et al (2008) Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 112:419–427. doi:10.1007/s10549-007-9879-y
Kobayashi H, Boelte KC, Lin PC (2007) Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 14:377–386
Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E (1998) Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 18:7095–7105
Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM (1988) Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature 334:629–631. doi:10.1038/334629a0
Logullo AF et al (2011) Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology 58:617–625. doi:10.1111/j.1365-2559.2011.03785.x
Milde-Langosch K (2005) The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41:2449–2461. doi:10.1016/j.ejca.2005.08.008
Milde-Langosch K, Bamberger AM, Goemann C, Rossing E, Rieck G, Kelp B, Loning T (2001) Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 127:537–544
Milde-Langosch K et al (2004) The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 86:139–152. doi:10.1023/B:BREA.0000032982.49024.71
Miles FL, Pruitt FL, van Golen KL, Cooper CR (2008) Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis 25:305–324. doi:10.1007/s10585-007-9098-2
Nakajima H et al (2007) Aberrant expression of Fra-1 in estrogen receptor-negative breast cancers and suppression of their propagation in vivo by ascochlorin, an antibiotic that inhibits cellular activator protein-1 activity. J Antibiot (Tokyo) 60:682–689. doi:10.1038/ja.2007.87
Nandy A, Jenatschke S, Hartung B, Milde-Langosch K, Bamberger AM, Gellersen B (2003) Genomic structure and transcriptional regulation of the human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene. J Mol Endocrinol 31:105–121
Oliveira-Ferrer L et al (2014) c-FOS suppresses ovarian cancer progression by changing adhesion. Br J Cancer 110:753–763. doi:10.1038/bjc.2013.774
Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46:1271–1277. doi:10.1016/j.ejca.2010.02.024
Petruzzelli L, Takami M, Humes HD (1999) Structure and function of cell adhesion molecules. Am J Med 106:467–476
Philips A, Teyssier C, Galtier F, Rivier-Covas C, Rey JM, Rochefort H, Chalbos D (1998) FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol 12:973–985
Potapenko IO et al (2010) Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol 4:98–118. doi:10.1016/j.molonc.2009.12.001
Richter U et al (2011) Adhesion of small cell lung cancer cells to E- and P-selectin under physiological flow conditions: implications for metastasis formation. Histochem Cell Biol 135:499–512. doi:10.1007/s00418-011-0804-4
Schroder C et al (2010) The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Cancer 46:1650–1660. doi:10.1016/j.ejca.2010.02.008
Shaulian E (2010) AP-1–the Jun proteins: Oncogenes or tumor suppressors in disguise? Cell Signal 22:894–899. doi:10.1016/j.cellsig.2009.12.008
Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131–136. doi:10.1038/ncb0502-e131
Smith LM et al (1999) cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18:6063–6070. doi:10.1038/sj.onc.1202989
Song Y et al (2006) An association of a simultaneous nuclear and cytoplasmic localization of Fra-1 with breast malignancy. BMC Cancer 6:298. doi:10.1186/1471-2407-6-298
Stinson S et al (2011) miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4:pt5. doi:10.1126/scisignal.2002258
Strell C, Entschladen F (2008) Extravasation of leukocytes in comparison to tumor cells. Cell Commun Signal 6:10
Tremblay PL, Huot J, Auger FA (2008) Mechanisms by which E-selectin regulates diapedesis of colon cancer cells under flow conditions. Cancer Res 68:5167–5176. doi:10.1158/0008-5472.CAN-08-1229
Usui A et al (2012) The molecular role of Fra-1 and its prognostic significance in human esophageal squamous cell carcinoma. Cancer 118:3387–3396. doi:10.1002/cncr.26652
Wagner EF, Eferl R (2005) Fos/AP-1 proteins in bone and the immune system. Immunol Rev 208:126–140. doi:10.1111/j.0105-2896.2005.00332.x
Young MR, Colburn NH (2006) Fra-1 a target for cancer prevention or intervention. Gene 379:1–11. doi:10.1016/j.gene.2006.05.001
Young MR et al (2002) Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol Cell Biol 22:587–598
Zajchowski DA et al (2001) Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61:5168–5178
Zen K et al (2008) CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration. PLoS One 3:e1826. doi:10.1371/journal.pone.0001826
Zhao C et al (2014) Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. Cancer Res 74:3983–3994. doi:10.1158/0008-5472.CAN-13-3396
Acknowledgments
We are very grateful to the excellent technical assistance of Maila Rossberg and Kathrin Eylmann.
Conflict of interest
All authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
L. Oliveira-Ferrer and M. Kürschner have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Oliveira-Ferrer, L., Kürschner, M., Labitzky, V. et al. Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties. J Cancer Res Clin Oncol 141, 1715–1726 (2015). https://doi.org/10.1007/s00432-015-1925-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-1925-2